Portal de Periódicos da CAPES

Renal insufficiency after intravenous immune globulin therapy

1997; American Society of Nephrology; Volume: 8; Issue: 11 Linguagem: Inglês

10.1681/asn.v8111788

1533-3450

Antonio V. Cayco, Mark A. Perazella, John P. Hayslett,

Mechanical Circulatory Support Devices

Over the past decade, intravenous immune globulin therapy (IVIG) has gained widespread use for a variety of clinical disorders. IVIG treatment is associated with a number of complications, including acute renal failure (ARF). Although the cause of IVIG-associated ARF is unknown, it may be related to the stabilizing agent used in the IVIG preparation. The development and resolution of ARF is typically rapid, but is some cases recovery may be delayed and require renal replacement therapy. In such patients, recurrence of ARF may be avoided by selection of a preparation with a different stabilizing agent. Two cases of IVIG-induced ARF are described, and all reported cases are analyzed to assess the probable mechanism of renal injury.